Citius Oncology, Inc. (CTOR)

In the past six months, Citius Oncology's stock reached a 52-week low of $0.9, reflecting a significant downturn. The company closed a $9.0 million registered direct offering and concurrent private placement in September 2025, followed by an $18 million offering in December 2025, to support the commercial launch of LYMPHIR. The FDA win for LYMPHIR was noted to be "Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption" and a shareholder alert regarding an investigation was announced in January 2026.

Information detailing the demand seasonality for Citius Oncology, Inc.'s products and services is not readily available. Demand for LYMPHIR is typically driven by disease incidence and patient needs rather than seasonal patterns.

Citius Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies. Its primary product, LYMPHIR™, is FDA-approved for treating adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL).

Citius Oncology is headquartered in Cranford, New Jersey, and launched LYMPHIR in the U.S. in December 2025. The company has established distribution agreements with the three largest U.S. pharmaceutical wholesalers and has expanded international access to LYMPHIR through Named Patient Programs in 19 markets.

Citius Oncology's brand reputation has been shaped by the FDA approval and U.S. commercial launch of LYMPHIR, the first new systemic therapy for cutaneous T-cell lymphoma patients in over seven years. The company has secured distribution agreements and expanded international access to LYMPHIR. However, the FDA win was noted to be "Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption," and a shareholder alert was issued regarding an investigation of Citius Oncology, Inc.

Citius Oncology has a mixed ownership structure including institutional investors, insiders, and retail investors. Major institutional shareholders include Armistice Capital, Llc, Vanguard Group Inc, and Geode Capital Management, Llc. Citius Pharmaceuticals Inc. is the largest individual shareholder, owning approximately 77.39% of Citius Oncology's shares. Insiders, including executives like Leonard L. Mazur, also hold a substantial portion of the stock.